Molecular targets for autoimmune and genetic disorders of neuromuscular transmission

European Journal of Biochemistry

Volumn 267, Issue 23, 2000, Pages 6717-6728

  Vincent, Angela ^a   Beeson, David ^a   Lang, Bethan ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acetylcholine receptor; Autoimmune; Genetic; Voltage gated calcium channel; Voltage gated potassium channel

Indexed keywords

ANTIBODY; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR; POTASSIUM CHANNEL;

AUTOIMMUNE DISEASE; EATON LAMBERT SYNDROME; GENE MUTATION; GENETIC DISORDER; HUMAN; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOKYMIA; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033711396     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2000.01785.x     Document Type: Review

References (92)

1. Synaptic structure and development. The neuromuscular junction
2. Formation of the neuromuscular junction. Agrin and its unusual receptors
3. Development of the vertebrate neuromuscular junction
4. Beta-spectrin is colocalized with both voltage-gated sodium channels and ankyrin G at the adult rat neuromuscular junction
5. The postysnaptic 43 K protein clusters muscle nicotinic acetylcholine receptors in Xenopus oocytes
6. Spatial relationships of utrophin, dystrophin, b-dystroglycan and b-spectrin to acetylcholine receptor clusters during postnatal maturation of the rat neuromuscular junction
7. Recent advances in chemistry and pharmacology of snake toxins
8. Calcium channel diversity and neurotransmitter release: The ω-conotoxins and ω-agatoxins
9. Effects of the potassium channel blocking dendrotoxins on acetylcholine release and motor nerve terminal activity
10. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins
11. The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor
12. Nicotinic acetylcholine receptor at 4.6 Å resolution: Transverse funnels in the channel wall
13. Alpha-bungarotoxin binding to human acetylcholine receptor; measurement of affinity, delineation of AChR subunit residues critical to binding, and protection of AChR function by synthetic peptides
14. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits
15. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor
16. Location of antigenic determinants on primary sequences of subunits of nicotinic acetylcholine receptor by peptide mapping
17. Precise epitope mapping of monoclonal antibodies to the cytoplasmic side of the acetylcholine receptor alpha subunit. Dissecting a potentially myasthenogenic epitope
18. Immunogenicity of human recombinant acetylcholine receptor α subunit. Cytoplasmic epitopes dominate the antibody response in four mouse strains
19. Autoantibody-mediated channelopathies at the neuromuscular junction
20. Venomous bites and stings in the tropical world
21. Myasthenia gravis
22. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis
23. Autoimmune response to acetylcholine receptor
24. Acetylcholine receptor: Complex of homologous subunits
25. Molecular structure of the nicotinic acetylcholine receptor
26. Neuromuscular junction in myasthenia gravis. Decreased acetylcholine receptors
27. Myasthenia gravis: A new hypothesis
28. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value
29. Function of circulating antibody to acetylcholine receptor in myasthenia gravis. Investigation by plasma exchange
30. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice
31. Myasthenia gravis and myasthenic syndromes
32. Experimental autoimmune myasthenia gravis
33. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis
34. Antibody heterogeneity and specificity in myasthenia gravis
35. Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform
36. Myasthenia antibodies cross-link acetylcholine receptors to accelerate degradation
37. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions
38. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis
39. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis: Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction
40. The membrane attack complex of complement at the endplate in myasthenia gravis
41. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis
42. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor
43. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen
44. Maturation of the acetylcholine receptor in developing skeletal muscle: Regulation of the AChR g to e switch
45. Association of arthrogryposis multiplex congenita with maternal antibodied inhibiting fetal acetylcholine receptor function
46. Asymptomatic maternal myasthenia as a cause of Pena-Shokeir phenotype
47. Plasma from human mothers of fetuses with severe arthrogyrposis multiplex congenita causes deformities in mice
48. Myasthenia gravis without acetylcholine receptor antibody: A distinct disease entity
49. Seronegative myasthenia gravis: A plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM
50. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function
51. Calcitonin gene-related peptide enhances the rate of desensitisation of the nicotinic acetylcholine receptor in cultured mouse muscle cells
52. IgG from 'seronegative' myasthenia gravis patients binds to a muscle cell line, TE671, but not human acetylcholine receptor
53. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis
54. The Lambert-Eaton myasthenic syndrome. A review of 50 cases
55. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma
56. Quantal components of end-plate potentials in the myasthenic syndrome
57. Paucity and disorganisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome
58. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome
59. Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse
60. Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate
61. 2+ channels in the mammalian central nervous system
62. Calcium channel blockers and transmitter release at the normal human neuromuscular junction
63. Structural and functional diversity of voltage-activated calcium currents
64. Decreased calcium currents in motor nerve terminals of mice with Lambert Eaton myasthenic syndrome
65. Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction
66. 2+ flux in a human small cell carcinoma line
67. Antagonism of voltage-gated calcium channels in small cell carcinomas of patients with and without Lambert-Eaton myasthenic syndrome by autoantibodies, W-conotoxin and adenosine
68. Heterogeneity of calcium channel autoantibodies detected using a small cell lung cancer line derived from a Lambert-Eaton syndrome patient
69. The role of autoantibodies in Lambert-Eaton myasthenic syndrome
70. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert Eaton myasthenic syndrome
71. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome
72. Calcium channel antibodies in the Lambert Eaton myasthenic syndrome and other paraneoplastic syndromes
73. Human autoantibodies specific for the alA calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons
74. Effect of Lambert Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse
75. Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology
76. Screening for autoantibodies in cerebellar ataxia
77. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review
78. Autoimmune aetiology for acquired neuromyotonia
79. + channels are implicated in neuromyotonia
80. Congenital myasthenia: End-plate acetylcholine receptors and electrophysiology in five cases
81. Congenital myasthenic syndromes
82. Novel functional ε-subunit polypeptide generated by a single nucleotide deletion in acetylcholine receptor deficiency congenital myasthenic syndrome
83. Mutation of the acetylcholine receptor ε-subunit promoter in congenital myasthenic syndrome
84. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel
85. Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity
86. Mutations in different functional domains of the human muscle acetylcholine receptor α subunits in patients with the slow-channel congenital myasthenic syndrome
87. The spectrum of mutations causing endplate acetylcholinesterase deficiency
88. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the calcium channel gene, CACNL1A4
89. Voltage-gated ion channels and hereditary disease